Arrowstreet Capital, Limited Partnership Zymeworks Inc. Transaction History

Arrowstreet Capital, Limited Partnership

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $2.39 Million - $3.44 Million	-90,111 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $584,608 - $1.11 Million	19,598 Added 27.79%	90,111 $2.85 Million
Q4 2020 Feb 12, 2021	BUY	$39.12 - $54.99 $2.76 Million - $3.88 Million	70,513 New	70,513 $3.33 Million
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $297,769 - $610,747	-12,264 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$24.84 - $45.46 $304,637 - $557,521	12,264 New	12,264 $558,000
Q2 2019 Aug 14, 2019	SELL	$15.0 - $22.49 $2.08 Million - $3.12 Million	-138,896 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$14.02 - $16.74 $1.43 Million - $1.71 Million	102,210 Added 278.61%	138,896 $2.25 Million
Q4 2018 Feb 14, 2019	BUY	$10.95 - $15.44 $277,976 - $391,959	25,386 Added 224.65%	36,686 $539,000
Q3 2018 Nov 14, 2018	BUY	$12.21 - $16.61 $137,973 - $187,693	11,300 New	11,300 $177,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $917M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.